Recent studies on mice reveal that a drug, being tested as an anticancer agent to treat breast cancer, supports recovery from muscular dystrophy, a disease that has no cure.
Duchene muscular dystrophy is a disease characterized by progressive weakness and degeneration of the muscles that control movement. According to earlier studies, the functional decline of "dystrophic" muscles can be slowed down by agents that enhance muscle fiber size.
The recent study conducted by Dr. P. L. Puri, from The Burnham Institute in La Jolla, California, and colleagues is published on line yesterday in the journal Nature Medicine. According to this study, the anticancer drug trichostatin A or TSA increases muscles fiber size in two mouse models of muscular dystrophy. Mice with this disability, when given TSA for 3 months, were able to run on treadmills and swim as long as healthy mice. According to the researchers, the drug caused no obvious side effects or signs of toxicity. TSA belongs to a class of drugs called deacetylase inhibitors.
Ms Sharon Hesterlee, a vice-president of the association, which helped finance the research, said "I am hesitant to call the finding a breakthrough, because that could raise expectations unfairly, but it's certainly an important finding."
Puri said, "Extensive investigation is now required to determine if these animal findings also apply to humans with muscular dystrophy. It is difficult to predict how long it will take before these studies will be translated into therapies for human patients," he added. "The next step is to test TSA on larger animals, such as golden retrievers, which contract a form of muscular dystrophy more similar to that in humans, " Dr Puri said.
One in every 3,500 male births is affected by this inherited disease. According to the Muscular Dystrophy Association, 40,000-60,000 people in the US have some form of the inherited disease.